[Effect of recombinant human erythropoietin on autologous blood donation for heart surgery].
Pharmacological stimulation of erythropoiesis was studied in patients selected for open heart surgery, and undergoing a programme of autologous blood predonation prior to surgery. Sixteen patients (group I: ery) received 4000 I. U. of recombinant human erythropoietin (r-huepo) subcutaneously weekly three times during a 3-week period preoperatively, another group of 21 patients (group II: control) were not given r-huepo. Patients in both groups received orally 2 x 80 mg iron daily. Predonation of five units of blood was planned in each patients, beginning on the 21. preoperative day; no blood was taken from patients if the hematocrit dropped below 0.34, or if any other complications occurred. The average amount of blood taken from patients in the ery group was 4.8 +/- 0.4 Units, and in the control group: 3.7 +/- 1.1 Units. In the ery group the planned 5 Units of blood could be taken from 13/16 patients, while in the controls only from 7/21. The differences are statistically significant. Reticulocyte counts were significantly higher consecutively during the preoperative period in the ery group than in the controls. In the postoperative period erythropoiesis was less pronounced in the ery group than in the controls. It is concluded that 1. r-huepo is an effective drug in preventing (or reducing) the anaemia due to repeated preoperative blood withdrawals, and thus larger amounts of autologous blood will be available for predonation. 2. More pronounced decrease of circulating reticulocytes observed in the postoperative period points to a possible suppression of endogenous erythropoietin production in the ery group.(ABSTRACT TRUNCATED AT 250 WORDS)
Szöcs
M
M
Szent-Györgyi Albert Orvostudományi Egyetem, Szeged, Szívsebészeti Onálló Osztály.
Donauer
E
E
Simon
J
J
Gál
G
G
Kovács
G
G
D016063:Blood Loss, Surgical; D001804:Blood Transfusion, Autologous; D006348:Cardiac Surgical Procedures; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
D011994:Recombinant Proteins; D004921:Erythropoietin
A rekombináns humán erythropoetin hatása a preoperatív autológ vérgyüjtésre szívmütétek kapcsán.